Trust the Worldwide CNS Experts with Your ALS Clinical Trial

Clinical research in therapies to address amyotrophic lateral sclerosis (ALS) faces many evolving challenges. Though still relatively rare, the incidence of this currently incurable neurodegenerative disease is rising. According to published research[i], the worldwide incidence of ALS is expected to increase by 69% between 2015 and 2040. Moreover, the research projects that the majority of new ALS cases will occur in developing nations, where populations are aging faster than they are in developed nations. For researchers working to thwart this deadly disease, these projections pose particular challenges: How can they gain access to suitable study participants? Where do they find the resources to run and manage trials in locations where they may have no footprint?

With 30+ years of experience supporting central nervous system research, Worldwide is an internationally acclaimed expert in the area of clinical trial management. We offer full-service Phase I–Phase IV and real-world evidence clinical research services for studies in ALS and other diseases affecting the CNS.

Our customers know that Worldwide will provide a stable project team of professionals already deeply experienced in CNS research. They turn to the Worldwide team for experienced insight into their development plan, detailed and expert feasibility analysis, and the capability to deliver their project on time and on budget.

With a global infrastructure spanning 60+ countries, Worldwide delivers access to an extensive international network of proven high-quality investigator sites. Our close relationships with opinion leaders and practitioners in CNS care ensure that complex study objectives and eligibility criteria evolve into a plan that delivers reliable metrics, consistently met timelines, and impeccable data.

[i] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987527/

 

.